Objective: To characterize B-cell subsets in patients with muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG).
. 20, 21 In all cases, the blood draw occurred more than 1 year after onset of symptoms. Nine patients had previously undergone thymectomy, and none of these patients had a thymoma or hyperplasia. The maximum MGFA severity class at any point after disease onset was at least moderate to severe generalized weakness (MGFA severity class III or IV) in all but 2 patients; 6 patients experienced "crisis" requiring mechanical intubation at some point after disease onset. Six patients were not on chronic immunotherapy at the time of the blood draw (1 completely treatment-naive); 1 patient had received a course of TPE 3 weeks prior to the blood sample and another received intermittent TPE. The remaining patients were on monotherapy with prednisone, cyclosporine, or mycophenolate mofetil, or combination therapy with these agents. Three patients had received rituximab infusions in the past.
Healthy controls. Blood samples were obtained from 9 healthy controls (6 women) weighing at least 110 pounds and not receiving treatment for another autoimmune disease. Controls were matched to the patients as closely as possible with regard to age and sex.
Isolation and storage of mononuclear peripheral blood cells. PBMCs were plated in 96-well round-bottom plates in RPMI 1 10% FBS (Gemini) 1 1% penicillin, streptomycin, and L-glutamine (Invitrogen, Carlsbad, CA). After centrifugation and removal of media, cells were surface stained with 50 mL of a cocktail mix consisting of titrated volumes of LIVE/DEAD violet dye (Life Technologies, Grand Island, NY); anti-CD3, anti-CD14, and CD16 Pacific Blue; anti-CD19 PcP-Cy5.5; anti-CD27 APC; anti-IgD PE; anti-CD20 FITC; anti-CD24 PE-Cy7 (BD Biosciences, San Jose, CA); and anti-CD38 APC-AF700 (Beckman Coulter, Brea, CA) (table 2). A "dump" channel consisting of LIVE/DEAD dye and CD3, CD14, and CD16 Pacific Blue was used to exclude dead cells, T cells, and monocytes. After fixing the cells with 1% paraformaldehyde (PFA), they were acquired on a LSRII flow cytometer (BD Biosciences, San Jose, CA).
Quantitative detection of BAFF. Quantitative detection of B cell-activating factor (BAFF) in plasma was performed using the Table 2 B-cell flow cytometry panel
Human BAFF Instant ELISA kit (eBioscience, San Diego, CA). Briefly, undiluted plasma was added to a microwell plate coated with lyophilized polyclonal antibody to human BAFF, biotin conjugate (anti-human BAFF polyclonal antibody), and sample diluent. Following incubation, unbound biotin-conjugated, antihuman BAFF antibodies are removed during a wash step, and a substrate reactive to horseradish peroxidase is added to the wells. The colored reaction is stopped using 1M phosphoric acid, and absorbance was measured at 450 nm using SpectraMax M2 microplate reader (Molecular Devices, Sunnyvale, CA).
B10 cell staining. Following previously published methods, 22 2 3 10 6 PBMCs resuspended in RPMI 1 10% FBS 1 1% penicillin, streptomcyin, and L-glutamine were stimulated with 10 mg/mL LPS (Sigma-Aldrich, St. Louis, MO) and 1 mg/mL CD40L (R&D Systems, Minneapolis, MN) for 48 hours at 37°C. 22 Forty-eight hours allows for the detection of both B10 and B10 progenitor cells, which are cells capable of maturing into IL-10 competent cells after stimulation. 22 For the final 5 hours of incubation, PMA (1 mg/mL, Sigma-Aldrich), ionomycin (0.25 mg/mL, Sigma-Aldrich), and brefeldin A (1:1,000 dilution, BD Biosciences) were added to the wells. After this period, cells were collected and stained with 50 mL of a cocktail mix consisting of titrated volumes of LIVE/DEAD violet dye; anti-CD3, anti-CD14, and anti-CD16 Pacific Blue; and anti-CD19 PcP Cy5.5 (BD Biosciences). Following a 30-minute incubation at 4°C, cells were treated with cytofix/cytoperm (BD Biosciences) according to the manufacturer's instructions. Then, anti-IL-10 Alexa Fluor 647 (eBiosciences) was added and incubated at 4°C for 30 minutes. Lastly, cells were fixed with 1% PFA and acquired on an LSRII flow cytometer (BD Biosciences). Data analysis and statistics. Flow cytometry data were analyzed using Flowjo software (Tree Star, Ashland, OR). B-cell subsets were summarized as percentages of the total B-cell population and log transformations were performed on immunologic data. Student t tests were used to determine statistical significance between groups, and p , 0.05 was set as the threshold for statistical significance. The p values and Pearson correlation coefficients were calculated with Prism software (Graph Pad, La Jolla, CA).
RESULTS MuSK antibodies. We quantitated MuSK autoantibody levels in plasma obtained concurrently with the B-cell analysis in patients previously diagnosed with MuSK MG (range 1.93-181.01 nmol/L). One patient had MuSK autoantibody levels below the 0.05 nmol/L positivity threshold and was excluded from the study. Notably, we observed an increase in MuSK autoantibody levels in patients with severe disease, as measured by MG-MMT scores (r 5 0.75; p 5 0.02), and there was a trend toward a negative correlation between MuSK autoantibody levels and disease duration that did not meet statistical significance (r 5 20.53; p 5 0.13) (data not shown). Our results suggest that unlike AChR MG, MuSK autoantibodies can be a novel biomarker for disease severity.
B-cell phenotypes in MuSK MG. We performed flow cytometry assays in accordance with a standardized Human Immunology Project Consortium panel that discriminates subsets of B cells, including naïve, memory, isotype-switched, transitional, and plasmablasts. 23 Three patients previously treated with rituximab (13-36 months prior to blood draw) had a dramatically different B-cell phenotype, with either nearly undetectable B cells or high percentages of transitional B cells and plasmablasts. 24 Because of these findings, which are consistent with prior reports of B-cell recovery after rituximab, these patients were excluded from all subsequent analyses. 25 We found no differences in the percentages of B-cell subsets or total B cells between healthy controls and patients with MuSK MG not treated with rituximab ( figure 1, A-C ) and no differences between immunosuppressed and nonimmunosuppressed patients (data not shown). These findings indicate that B-cell subset percentages are not altered in patients with MuSK MG.
BAFF analysis in MuSK MG. We also examined whether autoreactive B cells in MuSK MG were associated with increased BAFF levels. BAFF is essential for the survival, maturation, and homeostasis of B cells, and autoreactive B cells seem to be more dependent on BAFF for survival. 26, 27 Similar to other autoimmune diseases, we found higher concentrations of BAFF in patients with MuSK MG than in controls (figure 2A). However, examination of BAFF receptor expression revealed no differences in the mean percentages of CD19 1 cells from healthy controls (96.6%) and patients with MuSK MG (95.6%) (figure 2B) . There was no difference in BAFF levels between immunosuppressed and nonimmunosuppressed patients. Further analysis revealed that the highest plasma BAFF levels are found early in disease (r 5 20.70; p 5 0.008), but no effect was observed with regard to disease severity (figure 2, C and D). These findings suggest that higher BAFF levels could be a critical factor in the generation, maturation, and survival of MuSK MG autoreactive B cells.
B10 cells in MuSK MG. B10 cells are a regulatory subset of B cells characterized by their ability to produce IL-10. To determine whether breakdown in immune tolerance in MuSK MG may be attributable to a reduction in B10 cells, we performed a 48-hour in vitro stimulation to identify both B10 and B10 progenitor cells. 24 After intracellular cytokine staining, we observed a reduction of B cells capable of producing IL-10 in patients with MuSK MG (0.37% vs 1.23%; p 5 0.02) ( figure 3, A and B) . Further analysis of B10 cells demonstrated an increase in B10 percentages with higher BAFF concentrations (p 5 0.041) ( figure 3C ). In addition, there was no difference in B10 percentages between immunosuppressed and nonimmunosuppressed patients.
DISCUSSION MuSK MG is known to involve different IgG subtypes from AChR MG, different HLA associations and response to therapy, and reportedly fewer thymic changes. This suggests that these 2 forms of MG could have different immunopathologic mechanisms.
The cellular immunopathology of MuSK MG has not been extensively studied. In a recent study, we characterized T-cell responses in MuSK MG and found enhanced polyfunctional Th1 and Th17 responses. 13 However, there was no change in Treg percentages or the expression of CD39-a proposed marker of Treg function. Thus, the mechanism of In this study, we found no differences in the percentages of total B cells and B-cell subsets between controls and patients with MuSK not treated with rituximab. Peripheral BAFF levels were elevated in MuSK MG, as in AChR MG, [28] [29] [30] but there were no changes in the percentage of B cells expressing BAFF receptor. This suggests that secreted BAFF, which is produced by myeloid lineage cells and regulates B-cell survival and growth, but not BAFF receptor expression, may be more important in promoting autoreactive B cells in MuSK MG. We observed no other distinguishing features regarding BAFF levels except in early disease, where we found the highest levels of plasma BAFF. This suggests that interventions targeting BAFF may be more effective early in the disease.
Elevated BAFF levels have been found in other autoimmune diseases, but a targeted investigation had not been performed previously in MuSK MG. BAFF is an established focus for therapeutic intervention in autoimmune diseases, and the monoclonal antibody that targets BAFF, belimumab, has been approved for the treatment of systemic lupus erythematosus. 31 A clinical trial of belimumab in both AChR1 and MuSK MG is currently in progress. 32 Our findings support the inclusion of patients with MuSK in this trial, and it will be interesting to see whether interference with BAFF signaling has different effects on patients with AChR and MuSK MG.
Since our previous study did not find changes in Treg percentages in MuSK MG as a potential mechanism for a breakdown in self-tolerance, 13 we examined another subset of regulatory cells, the B10 cells, which are characterized by the production of the antiinflammatory cytokine IL-10. IL-10 produced by B10 cells potently inhibits antigen-specific inflammation and T cell-dependent autoimmune diseases. 33 On the other hand, elimination of B10 cells exacerbates autoimmune diseases in murine models of experimental autoimmune encephalomyelitis, chronic colitis, collagen-induced arthritis, and lupus. 16, 34, 35 Thus, B10 cells are increasingly recognized as vital to immune tolerance and modulating immune activation. The decreased percentages of B10 cells we found in MuSK MG could explain the previously observed increase in proinflammatory Th1 and Th17 responses and the breakdown in immune tolerance leading to the generation of autoreactive B cells in MuSK MG. 13 Alternatively, IL-10 has been demonstrated to promote the generation of plasma cells, whereas BAFF enhances the survival of plasmablasts. [36] [37] [38] [39] In our study, we observed an increase in B10 cell percentages in patients with higher BAFF levels ( figure 3C) ; however, elevated percentages of B10 cells or elevated BAFF levels did not equate to higher percentages of plasmablasts. Since the percentage of B10 cells in patients with MuSK MG is low, the small amount of IL-10 produced may be insufficient to drive plasmablast differentiation and noticeably increase their numbers.
A single previous study showed reduced B10 cell frequencies in a population of predominantly AChR MG patients who received rituximab. 19 Our observation of reduced B10 cell percentages in MuSK MG is in accord with these results. That study showed that repopulation of B10 cells occurred faster in rituximab responders, who also had higher B10 cell frequencies than nonresponders. This suggests that the clinical response in MuSK MG rituximab responders could involve B10 cell-mediated suppression of the proinflammatory Th1 and Th17 responses.
Confirming a previous study in which MuSK autoantibody levels increased with MGFA severity class and clinical score, 40 we found elevated levels of MuSK autoantibodies as the disease status became more severe. Whereas antibody levels are not reliable markers of disease severity, clinical status, or response to treatment in AChR autoantibody MG, 41, 42 autoantibody levels may be a potential biomarker for monitoring disease status in MuSK MG.
The relatively small sample size and heterogeneous treatment regimens and disease severity limit our ability to determine differential effects on B cells related to specific treatments or disease severity. Despite these limitations, this study of comprehensively characterized patients in this difficult-to-study population provides novel insights into the distinctive B-cell immunopathology in MuSK MG. Methods to identify MuSK-specific B cells, currently under development, will provide greater specificity for determining the mechanisms of MuSK MG pathology.
This study reports findings of elevated BAFF levels and decreased percentages of B10 cells in MuSK MG and supports the potential utility of MuSK antibodies as a biomarker of disease severity. BAFF-targeted therapies hold promise for MuSK MG treatment and should be further investigated. Along with a previous study of T cells, the emerging picture suggests that decreased B10 cell numbers may be critical to the loss of self-tolerance in MuSK MG. Without sufficient B10-derived anti-inflammatory IL-10, a permissive environment is created for enhanced BAFF signaling, autoantibody production, and Th1/Th17-mediated inflammation. Studies to increase the current understanding of the immunobiology of MuSK MG will require multicenter collaborations to recruit patients with this rare autoimmune disease.
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